Home Cart Sign in  
Chemical Structure| 1223405-08-0 Chemical Structure| 1223405-08-0

Structure of Larotrectinib sulfate
CAS No.: 1223405-08-0

Chemical Structure| 1223405-08-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LOXO-101 sulfate blocks the ATP binding site of the TRK family of receptors with IC50 of 2 nM to 20 nM against TRKA, TRKB, and TRKC.

Synonyms: LOXO-101 sulfate; ARRY-470 sulfate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Larotrectinib sulfate

CAS No. :1223405-08-0
Formula : C21H24F2N6O6S
M.W : 526.51
SMILES Code : O=S(O)(O)=O.O=C(N1CC[C@H](O)C1)NC2=C3N=C(N4[C@@H](C5=CC(F)=CC=C5F)CCC4)C=CN3N=C2
Synonyms :
LOXO-101 sulfate; ARRY-470 sulfate
MDL No. :MFCD29472286
InChI Key :PXHANKVTFWSDSG-QLOBERJESA-N
Pubchem ID :67330085

Safety of Larotrectinib sulfate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Larotrectinib sulfate

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A375 cells 10 μM 16 hours Larotrectinib enhanced the sensitivity of A375 cells to IFNγ, increasing CXCL10 expression PMC11377935
SK-MEL-2 cells 10 μM 16 hours Larotrectinib enhanced the sensitivity of SK-MEL-2 cells to IFNγ, increasing CXCL10 expression PMC11377935
HEK293 cells 5 μM 2.5 minutes Assess the uptake of Larotrectinib in HEK293 cells, showing that OATP1A2 increased the uptake of Larotrectinib, while OATP1B1, OATP1B3, and OATP2B1 did not significantly increase its uptake PMC7279963
B16 cells 10 μM 24 hours Larotrectinib enhanced the sensitivity of B16 cells to IFNγ, increasing Stat1 activation and Cxcl10 production PMC11377935
COLO205 cells 300 nM 24 hours Lar significantly suppressed the proliferation and migration of COLO205 cells and inhibited the epithelial-mesenchymal transition (EMT) process PMC9639042
HCT116 cells 300 nM 24 hours Lar significantly suppressed the proliferation and migration of HCT116 cells and inhibited the epithelial-mesenchymal transition (EMT) process PMC9639042
MDCK-II cells 5 μM 8 hours Assess the transepithelial transport of Larotrectinib in MDCK-II cells, showing that Larotrectinib was avidly transported by hABCB1 and mAbcg2, and efficiently by hABCG2 PMC7279963
DU145 20 nM overnight Larotrectinib significantly increased the expression of endogenous AGPS PMC10782585
22Rv1 20 nM overnight Larotrectinib significantly increased the expression of endogenous AGPS PMC10782585

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice B16 melanoma model Oral 200 mg/kg Daily for 60 days Larotrectinib combined with immunotherapy significantly improved the complete remission rate of melanoma, achieving a CR rate of >60% at the three-month mark, with 40% of animals achieving durable cure PMC11377935
SCID mice subcutaneous tumor xenograft model subcutaneous injection 300 mg/kg every 24 hours for 28 days Larotrectinib in combination with ML210 significantly inhibited tumor growth PMC10782585
Mice Genetically modified mouse models Oral 10 mg/kg Single dose, lasting 8 hours or 1 hour Assess the pharmacokinetic behavior of Larotrectinib in genetically modified mouse models, showing that ABCB1 and ABCG2 markedly limited the oral availability and brain accumulation of Larotrectinib, and OATP1A/1B and CYP3A also significantly affected its pharmacokinetics PMC7279963
Nude mice HCT116 xenograft model Intragastrically 20 mg/kg Twice daily for 3 weeks Lar significantly reduced tumour volume and weight in the HCT116 xenograft model and activated the AMPK/mTOR signalling pathway PMC9639042

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.50mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

References

 

Historical Records

Categories